clinical trial · NCT05353972
Evaluate IMG-007 in Healthy Participants
Inmagene LLC·phase1·completed·n = 44
Healthy ParticipantsIMG-007 or placebo
brief summary
This first in human (FIH) study will evaluate the safety, tolerability, pharmacokinetics (PK)), and immunogenicity of a single ascending dose of IMG-007 in healthy participants.
started
Jul 5, 2022
primary completion
May 31, 2023
completion
May 31, 2023
last updated
Jun 28, 2023
detailed description
This study is a double-blind, randomized, placebo-controlled, sequential ascending, single dose escalating (SAD) study to assess the safety and PK profile of IMG-007 in healthy participants. The study is comprised of 3 phases: screening phase, treatment phase, and safety follow-up phase.
official title
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IMG-007 in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol